BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

70.20
17 Apr 2014
Price Change (% chg)

0.20₪ (+0.28%)
Prev Close
70.20₪
Open
70.20₪
Day's High
71.40₪
Day's Low
70.20₪
Volume
435,702
Avg. Vol
1,492,786
52-wk High
117.00₪
52-wk Low
58.40₪

BLRX.TA

Chart for BLRX.TA

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)
No analyst recommendations are available for BLRX.TA.

Overall

Beta: 2.38
Market Cap (Mil.): ₪239.10
Shares Outstanding (Mil.): 339.64
Dividend: --
Yield (%): --

Financials

  BLRX.TA Industry Sector
P/E (TTM): -- 25.73 33.35
EPS (TTM): -0.47 -- --
ROI: -99.86 -2.92 18.92
ROE: -100.08 -12.17 19.68
Search Stocks

BRIEF-BioLine Rx U.S.-listed shares up 20.4 percent premarket

NEW YORK, Dec 16 - BioLine RX Ltd : * U.S.-listed shares up 20.4 percent to $3.07 in premarket after initial phase 2 results of acute myeloid leukemia treatment

16 Dec 2013

BRIEF-BioLine Rx U.S.-listed shares up 7.3 percent premarket

NEW YORK, Nov 26 - BioLine RX Ltd : * U.S.-listed shares up 7.3 percent premarket after phase 2a trial results for

26 Nov 2013

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$125.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks